C. Difficile

Researchers believe that an increased incidence of C. difficile in travelers returning from international destinations may be linked to travelers' diarrhea.

In a Phase 2 controlled clinical study, patients with Clostridium difficile infection receiving ridinilazole were found to have achieved better treatment outcomes than those receiving vancomycin.

What can healthcare providers do to stop these infections before they start?

Research coming in from the University of Texas Health Science Center at Houston shows that when it comes to treating those with C. difficile, frozen and freeze-dried products for Fecal Microbiota Transplantation are nearly as effective as fresh product.

News on Heliobacter pylori, Zika, Clostridium difficile, Powassan virus, and influenza make up the top 5 news articles from Contagion® in March 2017.

On March 30, 2017, at the SHEA Spring 2017 Conference, Thomas Sandora, MD, MPH, shared some tips regarding ways to manage movement outside of the room for patients who are on contact precautions.

Contagion® will be covering the conference, and so keep a look out for session coverage, as well as interviews with some of the key presenters.

In case you missed them, our top 5 articles for the week of March 19, 2017 are highlighted here.

Duke Health researchers have found that a UVC machine use can reduce transmission of harmful superbugs in hospital settings.

As emerging infectious diseases and resistant bugs become a growing issue, the need for stronger disinfectants becomes even more vital.

On March 5, 2017, at the 2017 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI), Gary Huang, MD, PhD, explained his research team's findings regarding self-reported allergy to drugs containing β-lactams.

Robin Jump, MD, PhD, assistant professor in the Department of Medicine at the Case Western Reserve University sat down with Contagion™ to discuss up-and-coming prevention methods for C. diff in the hospital setting.

In a new study, researchers found that patients with severe Clostridium difficile (C. diff) infections who were treated with vancomycin had lower mortality rates than patients who were treated with metronidazole.

A new study from the United Kingdom highlights the importance of antibiotic restriction in the reduction of hospital-acquired C. difficile infections.

Researchers found the experimental vaccine could potentially inhibit severe diarrhea and pseudomembranous colitis by inducing a functional antibody response that can neutralize the two main disease-causing toxins (toxin A or B) produced by C. difficile.

A new study has provided more evidence to show that certain heartburn medications may make individuals more susceptible to gastrointestinal infections.

A new study takes a look at the efficacy of off-label treatments for Clostridium difficile (C. difficile) infection.

Under a program established through the Affordable Care Act, 769 US hospitals will receive Medicare reimbursement reductions due to the high rates of hospital-acquired infections.

In mid-November, the CDC released the “Core Elements of Outpatient Antibiotic Stewardship.”

A study from University of Washington researchers uncovers how hospital laundry facilities may harbor dangerous Clostridium difficile spores, creating a potential community source for the bacterial pathogen.

Researchers at University of Chicago Medicine have created an antibiotic stewardship training program for internal medicine residents that incorporates social media platforms, offering a technological tool for a growing health problem.

A study using different criteria for urine testing than those outlined by the current Infectious Disease Society of America (IDSA) guidelines, has proven to cut down on the testing of urine samples and inappropriate use of antimicrobials.

Doctors at the Children’s Hospital Colorado have published their research on a new approach to antibiotic stewardship, with promising reductions in antibiotic use and rates of Clostridium difficile.

The US Food and Drug Administration has approved Merck’s Zinplava, a monoclonal antibody that will reduce recurrence of Clostridium difficile in high risk patients.

As hospitals continue to search for new ways to limit their number of patients acquiring Clostridium difficile (C. difficile) infections, a new study shows promise in the use of ultraviolet light technology for ridding patient rooms of highly resistant C. difficile spores.